To the Editor: Schernthaner et al. [1] and Nolan [2] describe several serious limitations of the ADA/EASD algorithm for the management of type 2 diabetes [3] . Unfortunately, they did not provide an alternative algorithm. Nolan [2] implies that therapy must be individualised to the extent that a general algorithm may not be needed or desired, but he provides no practical guide.
The American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE) recently published a new algorithm for the management of patients with type 2 diabetes [4] . This algorithm was developed by a panel of 14 clinical endocrinologists with extensive experience, who provide ongoing care to patients with type 2 diabetes. The AACE/ACE algorithm was also motivated by serious concerns regarding the limitations of the ADA/EASD algorithm. We would like to point out some of the most important differences between the AACE/ACE and the ADA/EASD algorithms. .6% and 9.0%, the AACE/ACE algorithm recommends moving directly to dual therapy, since it is highly unlikely that any monotherapy could achieve the goal of 6.5%. The highest priority is placed on combinations of metformin and incretin-based therapies, with a preference for GLP-1 agonists in view of their greater efficacy.
(Following the initial publication of the AACE algorithm, exenatide was approved for monotherapy in addition to its previous approval for combination therapy, and liraglutide was approved for combination therapy.) For patients with HbA 1c levels between 7.6% and 9.0%, sulfonylureas are given greater priority than glinides in view of their greater efficacy and lower risk for hypoglycaemia, and colesevelam and α-glucosidase inhibitors were not recommended in view of their lower efficacy. (3) For patients with HbA 1c levels above 9.0%, the AACE/ACE algorithm recommends initiating treatment with dual or triple therapy. The algorithm recommends moving directly to insulin therapy if the patient failed to achieve his/her target HbA 1c level on previous pharmacotherapy or is symptomatic because of hyperglycaemia. In all regimens it is essential to monitor therapy closely at 2 to 3 month intervals. If the patient has not achieved the desired goals for glycaemic control, therapy should be advanced-either by increasing dosage or by change of regimen.
The AACE/ACE review of the risks and benefits of various classes of medications (see Table 1 in [4] ) and considerations for selection of therapy is remarkably similar to that of Schernthaner et al. [1] . However, the AACE/ACE algorithm, available at www.aace.com/pub (accessed 28 August 2010), provides a flowchart or 'treatment path' (see Fig. 1 in [4] ) that is simple, clear, and provides meaningful priorities and guidance to the user [4] . It also provides more specific guidance than some alternatives [3, 5, 6] .
Schernthaner et al. [1] and Nolan [2] argue that algorithms should be evidence based. This would be desirable in principle but has not been attained in practice. Guidelines, such as the AACE guidelines [7] and ADA guidelines [8] , should be evidence based to the extent that sufficient, consistent evidence is available, with careful documentation of levels of evidence. Unfortunately, this inevitably results in a large document that is not likely to be sufficiently user friendly for quick reference by the physician at the point of care, which is perhaps one of the reasons that guidelines are rarely used at the point of care. In contrast, an algorithm [3] [4] [5] [6] can be short, simple and focused, and does not necessarily need to display, evaluate and cross-reference the evidence. Algorithms [3] [4] [5] [6] should be based on guidelines [7, 8] to the extent possible, and synthesised by a consensus of experts with extensive and appropriate clinical experience.
